Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV

10 de setembro de 2026 atualizado por: ViiV Healthcare

A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV

The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV). This study will be conducted following the availability of initial safety and PK clinical data from formulation of the parent drug VH4524184.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

160

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF).
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
  • Participants of any sex (male or female) are eligible. A female participant (female sex assigned at birth) is eligible to participate if they are a person of non-childbearing potential (PONCBP).
  • Capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

The criteria presented above represent a subset of the key inclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.

Exclusion Criteria:

  • History or presence of, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • History of drug hypersensitivity, delayed-type hypersensitivity or severe hypersensitivity reaction or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates study participation.
  • History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition in the opinion of the investigator.
  • Any preexisting physical or mental condition which, in the opinion of the investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Previous exposure to the parent molecule VH4524184.
  • Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention.
  • Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
  • Current enrolment or participation in another clinical study.
  • Any acute laboratory abnormality at screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
  • Positive HIV antibody/antigen test.
  • History of clinically relevant hepatitis within the last 6 months.
  • Positive hepatitis B or hepatitis C test.
  • Clinically significant cardiovascular disease..
  • QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec) and >480 msec (bundle branch block).
  • Blood pressure (BP) >140/90 (systolic BP/diastolic BP [SBP/DBP]).
  • Resting heart rate (HR) <50 or >100 beats per minute (bpm) when vital signs are measured at Screening or Check-in.

The criteria presented above represent a subset of the key exclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: VH5356136 Formulation 1
Participants will receive a single dose of VH5356136 Formulation 1 administered on Day 1.
Participants will receive VH5356136 Formulation 1 on Day 1.
Comparador de Placebo: Placebo for VH5356136 Formulation 1
Participants will receive a single dose of placebo for VH5356136 Formulation 1 administered on Day 1.
Participants will receive placebo for VH5356136 Formulation 1 on Day 1.
Experimental: VH5356136 Formulation 2
Participants will receive a single dose of VH5356136 Formulation 2 administered on Day 1.
Participants will receive VH5356136 Formulation 2 on Day 1.
Comparador de Placebo: Placebo for VH5356136 Formulation 2
Participants will receive a single dose of placebo for VH5356136 Formulation 2 administered on Day 1.
Participants will receive placebo for VH5356136 Formulation 2 on Day 1.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of participants with drug-related adverse events (AEs)
Prazo: From Day 1 to Month 18
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A drug-related AE is an AE that, in the opinion of the investigator, is related to one of the study interventions.
From Day 1 to Month 18
Number of participants with Grade 2 to Grade 5 AEs
Prazo: From Day 1 to Month 18
The grading of AEs is performed based on the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale, here Grade 2 = moderate, Grade 3=severe, Grade 4 = potentially life-threatening, Grade 5 = death.
From Day 1 to Month 18
Number of participants with serious adverse events (SAEs)
Prazo: From Day 1 to Month 18
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes.
From Day 1 to Month 18
Area under the concentration time curve from zero (pre-dose) to the last quantifiable concentration (post dose) (AUC[0-tlast]) for VH5356136
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
AUC(0-tlast) for VH4524184
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Maximum plasma concentration (Cmax) for VH5356136
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Cmax for VH4524184
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Time to maximum observed plasma drug concentration (tmax) for VH5356136
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Tmax for VH4524184
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Terminal half-life (t1/2) for VH5356136
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
t1/2 for VH4524184
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Prazo: From Day 1 (pre-dose) up to Month 18 post-dose
The laboratory abnormalities are assessed using the DAIDS grading scale, where Grade 3 = severe and Grade 4 = potentially life-threatening.
From Day 1 (pre-dose) up to Month 18 post-dose

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

6 de novembro de 2026

Conclusão Primária (Estimado)

9 de maio de 2029

Conclusão do estudo (Estimado)

9 de maio de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

10 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de setembro de 2026

Primeira postagem (Real)

16 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 300862

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

Prazo de Compartilhamento de IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Critérios de acesso de compartilhamento IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .